EA201690926A1 - Цитрат железа (iii) для уменьшения сердечной недостаточности у пациентов с хроническим заболеванием почек - Google Patents

Цитрат железа (iii) для уменьшения сердечной недостаточности у пациентов с хроническим заболеванием почек

Info

Publication number
EA201690926A1
EA201690926A1 EA201690926A EA201690926A EA201690926A1 EA 201690926 A1 EA201690926 A1 EA 201690926A1 EA 201690926 A EA201690926 A EA 201690926A EA 201690926 A EA201690926 A EA 201690926A EA 201690926 A1 EA201690926 A1 EA 201690926A1
Authority
EA
Eurasian Patent Office
Prior art keywords
iron
increase
patients
iii
reduce
Prior art date
Application number
EA201690926A
Other languages
English (en)
Russian (ru)
Inventor
Энрике Порадосу
Рон Бентсур
Джеймс Ф. Оливьеро III
Original Assignee
Керикс Байофармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Керикс Байофармасьютикалз, Инк. filed Critical Керикс Байофармасьютикалз, Инк.
Publication of EA201690926A1 publication Critical patent/EA201690926A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/26Iron; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EA201690926A 2013-11-04 2014-11-03 Цитрат железа (iii) для уменьшения сердечной недостаточности у пациентов с хроническим заболеванием почек EA201690926A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361899866P 2013-11-04 2013-11-04
PCT/US2014/063643 WO2015066593A1 (en) 2013-11-04 2014-11-03 Ferric citrate for reducing cardiac failure in chronic kidney disease patients

Publications (1)

Publication Number Publication Date
EA201690926A1 true EA201690926A1 (ru) 2016-09-30

Family

ID=53005244

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690926A EA201690926A1 (ru) 2013-11-04 2014-11-03 Цитрат железа (iii) для уменьшения сердечной недостаточности у пациентов с хроническим заболеванием почек

Country Status (15)

Country Link
US (3) US20160256486A1 (enExample)
EP (2) EP3747432A1 (enExample)
JP (3) JP2016535780A (enExample)
KR (1) KR102392441B1 (enExample)
CN (1) CN105873583A (enExample)
AU (1) AU2014341975A1 (enExample)
BR (1) BR112016009901A8 (enExample)
CA (1) CA2928200A1 (enExample)
EA (1) EA201690926A1 (enExample)
HK (1) HK1223031A1 (enExample)
IL (1) IL245317A0 (enExample)
MX (1) MX2016005734A (enExample)
SG (1) SG11201603091QA (enExample)
TW (2) TWI744215B (enExample)
WO (1) WO2015066593A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140016438A (ko) 2009-07-21 2014-02-07 케릭스 바이오파마슈티컬스 인코포레이티드 구연산철 투여형태
ES2834485T3 (es) 2013-06-05 2021-06-17 Tricida Inc Polímeros de unión a protones para administración oral
EP3157516A4 (en) 2014-06-22 2017-12-13 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
MA41150B1 (fr) 2014-12-10 2020-06-30 Tricida Inc Polymères de liaison aux protons pour administration orale
MA44875A (fr) 2016-05-06 2019-03-13 Tricida Inc Compositions pour le traitement de troubles acido-basiques
IL273960B2 (en) 2017-11-03 2025-08-01 Tricida Inc Nonabsorable compositions for use in treating or preventing metabolic acidosis
WO2020089227A1 (en) 2018-10-29 2020-05-07 Pharmacosmos Holding A/S Treating iron deficiency with ferric carboxymaltose
EA202191858A1 (ru) * 2019-06-12 2021-11-12 Фармакосмос Холдинг А/С Лечение дефицита железа у субъектов с риском нежелательных явлений со стороны сердечно-сосудистой системы и железо для лечения фибрилляции предсердий
TW202313072A (zh) * 2021-05-27 2023-04-01 美商凱立克斯生物製藥股份有限公司 檸檬酸鐵之兒科調配物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE351366B (enExample) * 1965-06-08 1972-11-27 Teikoku Hormone Mfg Co Ltd
US20050203169A1 (en) * 2001-08-06 2005-09-15 Moskowitz David W. Methods and compositions for treating diseases associated with excesses in ACE
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
US8093423B2 (en) * 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
EP2594551B1 (en) * 2005-08-18 2025-02-19 Panion & BF Biotech Inc. Uses of pharmaceutical-grade ferric organic compounds
KR20080106506A (ko) * 2006-01-30 2008-12-08 글로보아시아 엘엘씨 만성 신장병의 치료 방법
EP1978807B1 (en) * 2006-01-30 2016-03-23 Panion & BF Biotech Inc. Method of treating chronic kidney disease
KR20140016438A (ko) * 2009-07-21 2014-02-07 케릭스 바이오파마슈티컬스 인코포레이티드 구연산철 투여형태
JP5827326B2 (ja) * 2010-07-07 2015-12-02 アーデリクス,インコーポレーテッド リン酸輸送を阻害する化合物及び方法
PL3730136T3 (pl) * 2012-06-21 2024-03-25 Keryx Biopharmaceuticals, Inc. Zastosowanie cytrynianu żelaza(iii) w leczeniu pacjentów z przewlekłą chorobą nerek

Also Published As

Publication number Publication date
TW202203910A (zh) 2022-02-01
US20190307791A1 (en) 2019-10-10
MX2016005734A (es) 2016-11-08
JP2016535780A (ja) 2016-11-17
TWI744215B (zh) 2021-11-01
TW201609088A (zh) 2016-03-16
HK1223031A1 (zh) 2017-07-21
CN105873583A (zh) 2016-08-17
EP3065734A4 (en) 2017-05-17
BR112016009901A8 (pt) 2020-04-14
US20160256486A1 (en) 2016-09-08
JP2019206562A (ja) 2019-12-05
KR102392441B1 (ko) 2022-05-02
JP2021073230A (ja) 2021-05-13
JP6828100B2 (ja) 2021-02-10
SG11201603091QA (en) 2016-05-30
KR20160096597A (ko) 2016-08-16
CA2928200A1 (en) 2015-05-07
US20250360167A1 (en) 2025-11-27
WO2015066593A1 (en) 2015-05-07
IL245317A0 (en) 2016-06-30
EP3747432A1 (en) 2020-12-09
EP3065734A1 (en) 2016-09-14
AU2014341975A1 (en) 2016-05-19

Similar Documents

Publication Publication Date Title
EA201690926A1 (ru) Цитрат железа (iii) для уменьшения сердечной недостаточности у пациентов с хроническим заболеванием почек
MX2014015615A (es) Uso de citrato ferrico en el tratamiento de pacientes con enfermedad renal cronica.
EA201590849A1 (ru) Композиции, способы и применения для лечения диабета и связанных состояний посредством контроля уровня глюкозы крови
MX2017010734A (es) Terapia de combinacion con factores de coagulacion y anticuepos multiespecificos.
EA201890453A1 (ru) Анти-angptl8 антитела и их применение
MX2020010004A (es) Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos.
MX2019006259A (es) Transporte para atravesar la barrera hematoencefalica.
BR112015025955A2 (pt) tratamentos anticancerosos com anticorpos anti-egfr apresentando uma baixa fucosilação
EA201591762A1 (ru) Человеческие антитела к grem1
MX2020000083A (es) Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand.
Chavez et al. New insights into the regulation of vascular permeability
MX2020011190A (es) Angiotensina ii sola o en combinacion para usarse en el tratamiento de hipotension.
PE20141577A1 (es) Espray para heridas
EA201792418A1 (ru) Применение cd24 для снижения уровней холестерина липопротеинов низкой плотности
EA201990403A1 (ru) Человеческие анти-vegfr-2/kdr-антитела
MX2015009968A (es) Metodos para tratar deficiencias de hierro con pirofosfato ferrico soluble.
WO2010119991A3 (en) Anti-hgf antibody combinational cancer therapies
PH12015502301A1 (en) Microporous zirconium silicate and diuretics for the reduction of potassium and treatment of chronic kidney and/or chronic heart disease
EA202090028A1 (ru) Способы уменьшения или предотвращения сердечно-сосудистых явлений у пациентов с сахарным диабетом ii типа
EA201790790A1 (ru) Антитела человека против vegfr-2/kdr
RU2013155841A (ru) Способ ранней диагностики хронической болезни почек
BR112014032781A2 (pt) dispositivo para aumentar fluxo sanguíneo, perfusão tecidual e distribuição de fluidos por estimulação neuromuscular em cavalos e outros mamíferos não-humanos
UA62757U (ru) Способ прогнозирования адекватности программного гемодиализа у больных с хронической болезнью почек v стадии
RU2013110191A (ru) Способ определения предикторной значимости мозгового натрийуретического пептида у больных хронической болезнью почек, получающих терапию программным гемодиализом
Chairkin et al. CHANGE IN THE STRUCTURE OF THE ADRENAL CORTEX ON THE FIRST DAY AFTER ACUTE BLOOD LOSS